The futility of thrombophilia testing

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 4, 2014, Pages 499-503

  Favaloro, Emmanuel J ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

acquired thrombophilia; antiphospholipid antibodies; antithrombin; Factor V Leiden; inherited thrombophilia; protein C; protein S; prothrombin mutation; testing

Indexed keywords

ANTITHROMBIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 5 LEIDEN; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN; BLOOD CLOTTING FACTOR 5;

ADVERSE OUTCOME; ANTITHROMBIN DEFICIENCY; ARTICLE; HEMOSTASIS; MUTATION; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK ASSESSMENT; THROMBOPHILIA; THROMBOSIS; ANTITHROMBIN III DEFICIENCY; DIAGNOSTIC PROCEDURE; GENETICS; HUMAN;

ANTITHROMBIN III DEFICIENCY; CLINICAL LABORATORY TECHNIQUES; FACTOR V; HUMANS; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; THROMBOPHILIA;

EID: 84896784854     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0560     Document Type: Article

References (17)

1. Coppola A, Tufano A, Cerbone AM, Di Minno G. Inherited thrombophilia: implications for prevention and treatment of venous thromboembolism. Semin Thromb Hemost 2009;35:83-94.
2. Franchini M, Veneri D, Salvagno GL, Manzato F, Lippi G. Inherited thrombophilia. Crit Rev Clin Lab Sci 2006;43:249-90.
3. Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? Semin Thromb Hemost 2012;38:322-7.
4. Schulman S. Optimal duration of anticoagulant therapy. Semin Thromb Hemost 2013;39:141-6.
5. Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. Semin Thromb Hemost 2013;39:117-26.
6. Tripodi A. Problems and solutions for testing hemostasis assays while patients are on anticoagulants. Semin Thromb Hemost 2012;38:586-92.
7. Favaloro EJ, Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem Med (Zagreb) 2012;22:329-41.
8. Favaloro EJ, McDonald D, Lippi G. Laboratory investigation of thrombophilia: the good, the bad, and the ugly. Semin Thromb Hemost 2009;35:695-710.
9. Favaloro EJ, Mohammed S, Pati N, Manyuk H, McDonald D. A clinical audit of congenital thrombophilia investigation in tertiary practice. Pathology 2011;43:266-72.
10. Favaloro EJ. Futility of testing for factor V Leiden. Blood Transfus 2012;10:260-3.
11. Galli M. Interpretation and recommended testing for antiphospholipid antibodies. Semin Thromb Hemost 2012;38:348-52.
12. Favaloro EJ, Wheatland L, Jovanovich S, Roberts-Thomson P, Wong RC. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I-anticardiolipin and anti-β2- glycoprotein I antibodies. Semin Thromb Hemost 2012;38: 390-403.
13. Favaloro EJ. Trials and tribulations in lupus anticoagulant testing. Clin Chem Lab Med 2013;51:253-6.
14. Favaloro EJ, Reben R, Mohammed S, Koutts J. A clinical audit of antiphospholipid antibody testing in tertiary practice. Towards improved relevance in thrombophilia investigations? Internal Med J 2012;42:427-34.
15. Les I, Ruiz-Irastorza G, Khamashta MA. Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. Semin Thromb Hemost 2012;38:339-47.
16. Goy J, Crowther M. Approaches to diagnosing and managing anticoagulant-related bleeding. Semin Thromb Hemost 2012;38:702-10.
17. Franchini M. Utility of testing for factor V Leiden. Blood Transfus 2012;10:257-9.